# Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients

> **NCT02642458** · — · UNKNOWN · sponsor: **University Hospital Tuebingen** · enrollment: 300 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02642458
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2020-03
- **Final completion:** 2020-07
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02642458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02642458, "Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02642458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*